Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens

Medtronic (NYSE: MDT) announced strategic investments in two ICE catheter developers, Beluga Medical in California and CardioACC in Shenzhen, China, to support future expansion of its cardiac ablation portfolio.

Rhea-AI Summary

Medtronic (NYSE: MDT) announced strategic investments in two ICE catheter developers, Beluga Medical in California and CardioACC in Shenzhen, China, to support future expansion of its cardiac ablation portfolio.

Medtronic plans to integrate intracardiac echocardiography into its Affera mapping and ablation system to enhance electrophysiology workflows and strengthen the Affera ecosystem.

Positive

• Strategic investments in two ICE catheter companies to enhance cardiac ablation portfolio
• Planned integration of ICE imaging into the Affera mapping and ablation system
• CardioACC ICE system already approved by China’s National Medical Products Administration in 2025

Negative

• None.

Argus Jun 3 session

+5.69% close to close Open Argus

Details

News Market Reaction – MDT

In the Jun 3 session, MDT gained 5.69%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Med...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Medtronic’s focus on high-growth cardiovascular technologies. The company recently posted Q4 revenue of $9.807 billion and FY26 revenue of $36.364 billion, with cardiovascular growth of 12.0%, so new ICE catheter investments fit an established expansion track. Investors would still need to weigh longer-term execution risks and existing shelf capacity for debt issuance when assessing durability of any outsized move.

Key Figures

Q4 2026 revenue: $9.807 billion Q4 2026 non-GAAP EPS: $1.55 FY 2026 revenue: $36.364 billion +5 more

Q4 2026 revenue

$9.807 billion

Fiscal Q4 2026; up 9.9% reported and 6.6% organic vs prior year

Q4 2026 non-GAAP EPS

$1.55

Fiscal Q4 2026; ahead of guidance per 8-K

FY 2026 revenue

$36.364 billion

Full-year 2026; up 8.4% reported and 5.8% organic

FY 2026 free cash flow

$5.426 billion

Full-year 2026 free cash flow generation

Quarterly dividend

$0.72 per share

Raised dividend; 49th consecutive annual increase

FY 2027 organic growth guide

6.75%–7.25%

Guided organic revenue growth range for FY27

FY 2027 non-GAAP EPS guide

$5.90–$6.00

Guided diluted non-GAAP EPS for FY27; implies 6.7%–8.5% growth

Cardiovascular revenue growth

12.0%

FY 2026 cardiovascular segment revenue growth reported

Historical Context

5 past events · Latest: May 20

5 events

1. May 20

   Chronic pain acquisition

   24h Move

   -1.3%

   Planned $650M cash acquisition of SPR Therapeutics to expand chronic pain care.

2. Apr 28

   CE Mark win

   24h Move

   -1.2%

   CE Mark for Stealth AXiS surgical system expanding European spine and cranial use.

3. Apr 20

   Cardio acquisition close

   24h Move

   -1.4%

   Completed $585M CathWorks acquisition adding AI-driven FFRangio cardiovascular system.

4. Apr 13

   Earnings date set

   24h Move

   +0.9%

   Scheduled Q4 and full-year FY26 earnings release and webcast timing details.

5. Mar 27

   FDA clearance

   24h Move

   -0.6%

   FDA clearance for Stealth AXiS system for cranial and ENT procedures.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intracardiac echocardiography, ICE catheters, electrophysiology, atrial fibrillation

4 terms

intracardiac echocardiography medical

"Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment..."

A type of medical imaging where a small ultrasound probe is threaded into the heart on a thin tube to take real‑time pictures from inside the body, like moving a camera into a machine to see its parts up close. Investors care because this tool can improve the safety, speed and success of cardiac procedures, affecting demand for the device makers, hospital costs, procedure volumes and potential regulatory or reimbursement outcomes.

ICE catheters medical

"ICE catheters provide real-time, high-resolution imaging of the heart during..."

A medical device that is a thin, flexible tube with a tip that cools or creates ice to freeze and destroy targeted tissue inside the body, most often used to treat abnormal heart rhythms or remove small lesions without cutting. For investors, ice catheters matter because they are specialized products whose sales, approvals, and adoption can drive medical-device revenue and signal clinical trends—think of them as a frozen scalpel that offers an alternative approach to surgery with potential cost, safety, and competitive implications.

electrophysiology medical

"ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures..."

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

atrial fibrillation medical

"EP procedures for cardiac arrhythmias such as atrial fibrillation (Afib)."

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologies

GALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera™ mapping and ablation system to continue building on the differentiated value proposition of the Affera ecosystem.

The investments further reinforce the momentum of the cardiac ablation business at Medtronic and include Beluga Medical, a premarket-stage company located in California developing a next-generation ICE product, and CardioACC, an early commercial-stage company based in Shenzhen, China. CardioACC received National Medical Products Administration approval for its ICE system in 2025.

"The incredible growth of our business demonstrates the demand for better technologies in electrophysiology, and we are leaning into opportunities that support our long-term portfolio roadmap," said Rebecca Seidel, president of the Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio. "ICE catheters are an important component of ablation procedures today, and we intend for our Affera platform to evolve to include this capability. These investments represent another step to support expansion of our leadership position in EP as we work to bring new and innovative technologies to each market."

The investments in cardiac ablation continue the recent cadence of strategic transactions at Medtronic to strengthen the company's leadership within its core franchises. Medtronic continues to prioritize high-growth opportunities to complement its core businesses and deliver sustained value for physicians and hospital partners.

"Intracardiac echocardiography has become a procedural essential in electrophysiology, giving physicians real-time visualization that can support more confident decision making throughout an ablation case," said Khaldoun Tarakji, M.D., MPH, vice president, chief medical officer, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "By investing in ICE technologies, we are strategically positioning ourselves to evolve and strengthen the Affera ecosystem over time, with the goal of continuing to advance integrated imaging and mapping workflows, improve procedural efficiency, and deliver better outcomes for patients."

Both ICE catheter companies will continue to operate independently.

About the Medtronic Cardiac Ablation Solutions Business 
Medtronic was the first company with two pulsed field ablation (PFA) offerings for physicians and patients. The PulseSelect™ Pulsed Field Ablation System offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) and is now available in more than 35 countries.

Sphere-9™ is the only all-in-one, dual energy mapping and ablation catheter for treatment of persistent AFib and concomitant CTI-dependent atrial flutter. The Affera system, together with the Sphere-9 catheter, enables physician treatment flexibility with its wide area focal design and 9 mm lattice. Sphere-9 is approved in the U.S., Europe, Australia, New Zealand and Japan, with global expansion ongoing. 

The Sphere-360 catheter is approved in Europe and investigational in the United States. For more information on the Affera system, the Sphere-9 catheter and the Sphere-360 catheter, visit Medtronic.com.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Leslie Williamson
Public Relations
+1-612-227-5099

Ingrid Goldberg
Investor Relations
 +1-763-505-2696

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-strategic-investments-to-support-future-expansion-of-cardiac-ablation-portfolio-as-physician-demand-for-affera-technologies-broadens-302789277.html

SOURCE Medtronic plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What strategic investments did Medtronic (NYSE: MDT) announce on June 3, 2026?

Medtronic announced strategic investments in Beluga Medical and CardioACC, two privately held intracardiac echocardiography (ICE) catheter companies. According to Medtronic, these investments aim to support future expansion of its cardiac ablation portfolio and strengthen its Affera mapping and ablation ecosystem.

How will the ICE investments impact Medtronic’s Affera cardiac ablation platform (MDT)?

Medtronic intends to integrate ICE imaging into the Affera mapping and ablation system. According to Medtronic, adding intracardiac echocardiography is expected to advance integrated imaging and mapping workflows, improve procedural efficiency in electrophysiology, and support better outcomes for patients undergoing ablation procedures.

Who are Beluga Medical and CardioACC in Medtronic’s June 2026 ICE investment news?

Beluga Medical is a premarket-stage California company developing a next-generation ICE product, while CardioACC is an early commercial-stage ICE company in Shenzhen, China. According to Medtronic, both firms will continue operating independently following these strategic investments.

What regulatory milestone has CardioACC achieved related to its ICE system before Medtronic’s MDT investment?

CardioACC received National Medical Products Administration approval in China for its ICE system in 2025. According to Medtronic, this early commercial-stage status complements its cardiac ablation strategy and supports broader adoption of intracardiac echocardiography in electrophysiology procedures.

Why is Medtronic investing in intracardiac echocardiography technologies for cardiac ablation?

Medtronic views intracardiac echocardiography as a procedural essential in electrophysiology. According to Medtronic, ICE offers real-time, high-resolution heart imaging that can support more confident decision-making, enhance Affera platform capabilities, and align with the company’s focus on high-growth cardiac ablation opportunities.